MX2020004894A - Composiciones que comprenden un inhibidor de demetilasa-1 especifico de lisina. - Google Patents

Composiciones que comprenden un inhibidor de demetilasa-1 especifico de lisina.

Info

Publication number
MX2020004894A
MX2020004894A MX2020004894A MX2020004894A MX2020004894A MX 2020004894 A MX2020004894 A MX 2020004894A MX 2020004894 A MX2020004894 A MX 2020004894A MX 2020004894 A MX2020004894 A MX 2020004894A MX 2020004894 A MX2020004894 A MX 2020004894A
Authority
MX
Mexico
Prior art keywords
inhibitor
specific demethylase
lysine specific
compositions
lysine
Prior art date
Application number
MX2020004894A
Other languages
English (en)
Inventor
Stephen W Kaldor
Jeffrey Alan Stafford
Young K Chen
James Marvin Veal
Matthew Michael Kreilein
Touflke KANOUNI
Paula Alessandra Tavaresgreco
Original Assignee
Celgene Quanticel Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Quanticel Res Inc filed Critical Celgene Quanticel Res Inc
Publication of MX2020004894A publication Critical patent/MX2020004894A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se describen en la presente formas amorfas y cristalinas de sales farmacéuticamente aceptables del inhibidor de demetilasa-1 específico de lisina, 4-(2-(4-amino-piperidin-1-il)-5-(3-fluoro-4- metoxi-fenil)-1-metil-6-oxo-1, 6-dihidro-pirimidin-4-il)-2-fluorob enzonitrilo. También se describen composiciones farmacéuticas adecuadas para administración a un mamífero que incluye el inhibidor de demetilasa-1 específico de lisina, y métodos para utilizar el inhibidor de demetilasa-1 específico de lisina para tratar enfermedades o condiciones que están asociadas con la actividad de demetilasa-1 específica de lisina.
MX2020004894A 2015-11-05 2016-11-04 Composiciones que comprenden un inhibidor de demetilasa-1 especifico de lisina. MX2020004894A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562251507P 2015-11-05 2015-11-05
PCT/US2016/060694 WO2017079670A1 (en) 2015-11-05 2016-11-04 Compositions comprising an inhibitor of lysine specific demethylase-1

Publications (1)

Publication Number Publication Date
MX2020004894A true MX2020004894A (es) 2021-11-03

Family

ID=58662888

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020004894A MX2020004894A (es) 2015-11-05 2016-11-04 Composiciones que comprenden un inhibidor de demetilasa-1 especifico de lisina.
MX2018005620A MX2018005620A (es) 2015-11-05 2016-11-04 Composiciones que comprenden un inhibidor de demetilasa-1 especifico de lisina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2018005620A MX2018005620A (es) 2015-11-05 2016-11-04 Composiciones que comprenden un inhibidor de demetilasa-1 especifico de lisina.

Country Status (20)

Country Link
US (4) US9828358B2 (es)
EP (1) EP3371152B1 (es)
JP (1) JP6995043B2 (es)
CN (1) CN108473442B (es)
AR (1) AR106612A1 (es)
AU (1) AU2016349707B2 (es)
CA (1) CA3004300C (es)
CY (1) CY1124078T1 (es)
DK (1) DK3371152T3 (es)
ES (1) ES2846951T3 (es)
HR (1) HRP20210144T8 (es)
HU (1) HUE053449T2 (es)
LT (1) LT3371152T (es)
MX (2) MX2020004894A (es)
PL (1) PL3371152T3 (es)
PT (1) PT3371152T (es)
RS (1) RS61404B1 (es)
SI (1) SI3371152T1 (es)
TW (1) TW201720808A (es)
WO (1) WO2017079670A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9255097B2 (en) 2014-05-01 2016-02-09 Quanticel Pharmaceuticals, Inc. Inhibitors of lysine specific demethylase-1
PL3371152T3 (pl) * 2015-11-05 2021-06-28 Celgene Quanticel Research, Inc. Kompozycje zawierające inhibitor specyficznej dla lizyny demetylazy-1 mający pierścień pirymidynowy i jego zastosowanie w leczeniu nowotworów
US20190256930A1 (en) 2016-11-03 2019-08-22 Oryzon Genomics, S.A. Biomarkers for determining responsiveness to lsd1 inhibitors
US20200069677A1 (en) 2016-12-09 2020-03-05 Constellation Pharmaceuticals, Inc. Markers for personalized cancer treatment with lsd1 inhibitors
MX2020001323A (es) 2017-08-03 2020-03-20 Oryzon Genomics Sa Metodos para tratar alteraciones del comportamiento.
AU2020242302A1 (en) 2019-03-20 2021-09-16 Oryzon Genomics, S.A. Methods of treating borderline personality disorder
JP2022526755A (ja) 2019-03-20 2022-05-26 オリソン ヘノミクス，ソシエダ アノニマ 化合物バフィデムスタット（ｖａｆｉｄｅｍｓｔａｔ）などｋｄｍ１ａ阻害剤を使用した注意欠陥多動性障害の処置方法
EP3983016A4 (en) * 2019-06-13 2023-06-07 Celgene Corporation METHODS OF TREATMENT OF CANCER BY TARGETING COLD TUMORS
JP2022537384A (ja) * 2019-06-20 2022-08-25 セルジーン コーポレーション ベネトクラクス、ギルテリチニブ、ミドスタウリン、または白血病もしくは骨髄異形成症候群を治療するための他の化合物との組み合わせにおけるアザシチジン
CN114341366A (zh) 2019-07-05 2022-04-12 奥莱松基因组股份有限公司 用于使用kdm1a抑制剂个体化治疗小细胞肺癌的生物标志物和方法
CN116056707A (zh) * 2020-06-05 2023-05-02 赛尔基因昆蒂赛尔研究公司 治疗前列腺癌的方法
ES2919083R1 (es) * 2020-06-29 2022-07-26 Celgene Quanticel Res Inc Métodos de tratamiento de cáncer de próstata
CA3231846A1 (en) 2021-04-08 2022-10-13 Tamara Maes Combinations of lsd1 inhibitors for treating myeloid cancers
WO2023217758A1 (en) 2022-05-09 2023-11-16 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
WO2023217784A1 (en) 2022-05-09 2023-11-16 Oryzon Genomics, S.A. Methods of treating nf1-mutant tumors using lsd1 inhibitors
WO2024110649A1 (en) 2022-11-24 2024-05-30 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
CA2513414A1 (en) * 2002-04-10 2003-10-16 Orchid Chemicals & Pharmaceuticals Limited Pyrimidinedione derivatives useful for the treatment of inflammation and immunological diseases
AU2003216585A1 (en) * 2002-04-10 2003-10-20 Orchid Chemicals And Pharmaceuticals Limited Pyrimidinedione derivatives useful for the treatment of inflammation and immunological diseases
US20070270446A1 (en) * 2004-10-06 2007-11-22 Smithkline Beecham Corporation Reversed Pyrimidinone Compounds as Calcilytics
US20100137313A1 (en) * 2008-10-03 2010-06-03 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
US10093646B2 (en) * 2014-01-17 2018-10-09 Novartis Ag 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2
US9255097B2 (en) * 2014-05-01 2016-02-09 Quanticel Pharmaceuticals, Inc. Inhibitors of lysine specific demethylase-1
PL3371152T3 (pl) * 2015-11-05 2021-06-28 Celgene Quanticel Research, Inc. Kompozycje zawierające inhibitor specyficznej dla lizyny demetylazy-1 mający pierścień pirymidynowy i jego zastosowanie w leczeniu nowotworów

Also Published As

Publication number Publication date
CA3004300C (en) 2023-08-22
CN108473442A (zh) 2018-08-31
LT3371152T (lt) 2021-04-12
CN108473442B (zh) 2022-03-25
US20180319767A1 (en) 2018-11-08
AU2016349707B2 (en) 2020-12-10
EP3371152B1 (en) 2020-12-23
SI3371152T1 (sl) 2021-06-30
HRP20210144T1 (hr) 2021-03-05
PL3371152T3 (pl) 2021-06-28
US10316016B2 (en) 2019-06-11
RS61404B1 (sr) 2021-02-26
TW201720808A (zh) 2017-06-16
CY1124078T1 (el) 2022-05-27
CA3004300A1 (en) 2017-05-11
WO2017079670A1 (en) 2017-05-11
WO2017079670A9 (en) 2017-06-15
US10047069B2 (en) 2018-08-14
EP3371152A4 (en) 2019-07-03
ES2846951T3 (es) 2021-07-30
HUE053449T2 (hu) 2021-06-28
PT3371152T (pt) 2021-02-01
JP6995043B2 (ja) 2022-02-04
US20180044320A1 (en) 2018-02-15
DK3371152T3 (da) 2021-02-15
US20170129871A1 (en) 2017-05-11
HRP20210144T8 (hr) 2021-04-16
EP3371152A1 (en) 2018-09-12
MX2018005620A (es) 2018-08-01
US20190367473A1 (en) 2019-12-05
US10703739B2 (en) 2020-07-07
AU2016349707A1 (en) 2018-05-24
AR106612A1 (es) 2018-01-31
US9828358B2 (en) 2017-11-28
JP2019500323A (ja) 2019-01-10

Similar Documents

Publication Publication Date Title
MX2020004894A (es) Composiciones que comprenden un inhibidor de demetilasa-1 especifico de lisina.
MX2020010484A (es) Derivados de heterociclilos sustituidos como inhibidores de cdk.
MX2021009673A (es) Moduladores de ror-gamma.
PH12017500583A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
PH12016501457B1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
WO2016044556A3 (en) Arginine methyltransferase inhibitors and uses thereof
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
PH12016502005A1 (en) Compounds and compositions for inducing chondrogenesis
MX2015012850A (es) Inhibidores de la arginina metiltransferasa y usos de los mismos.
MX2018009257A (es) Derivados de benzimidazol como moduladores de ror-gamma.
WO2014179564A8 (en) Thiazolopyrrolidine inhibitors of ror-gamma
MX2016011105A (es) Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos.
EA201791021A1 (ru) 1-[2-(АМИНОМЕТИЛ)БЕНЗИЛ]-2-ТИОКСО-1,2,3,5-ТЕТРАГИДРО-4H-ПИРРОЛО[3,2-d]ПИРИМИДИН-4-ОНЫ КАК ИНГИБИТОРЫ МИЕЛОПЕРОКСИДАЗЫ
PH12017500089A1 (en) Aldosterone synthase inhibitors
MX2016009621A (es) Derivados de fur0-3-carboxamida y metodos de uso.
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MX2017001869A (es) Formas cristalinas de un modulador de receptor de estrogeno.
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
TW201613600A (en) Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically
UA102355U (ru) Способ лечения рецидивирующей формы фибрилляции предсердий у больных с ишемической болезнью сердца
MX2016010919A (es) 4-bencilsulfonil-2-butenonitrilo.
IN2014DE00822A (es)